Arrowhead Research Newswire

Arrowhead Research Newswire

Comprehensive Real-Time News Feed for Arrowhead Research.

Results 1 - 20 of 352 in Arrowhead Research

  1. Arrowhead Pharmaceuticals (ARWR) Lifted to Strong-Buy at BidaskClubRead the original story w/Photo

    Yesterday | IntersportsWire

    Other analysts have also issued research reports about the company. ValuEngine raised Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 2nd.

    Comment?

  2. Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseRead the original story w/Photo

    Yesterday | Business Wire

    Two planned cohorts at a dose of 400 mg were eliminated because maximal activity appeared to occur at lower doses than expected. The company intends to submit a late-breaking abstract with initial clinical data on ARO-AAT to the Liver MeetingA , the Annual Meeting of the American Association for the Study of Liver Disease , being held in November 2018.

    Comment?

  3. BidaskClub Upgrades Arrowhead Pharmaceuticals (ARWR) to Strong-BuyRead the original story w/Photo

    Sunday | Daily Political

    A number of other brokerages have also issued reports on ARWR. Cantor Fitzgerald reiterated a "buy" rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 30th.

    Comment?

  4. Arrowhead Pharmaceuticals Inc (ARWR) Given Consensus Recommendation of "Buy" by AnalystsRead the original story w/Photo

    Friday Jun 15 | AmericanBankingNews.com

    Shares of Arrowhead Pharmaceuticals Inc have earned an average rating of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company.

    Comment?

  5. Acuta Capital Partners LLC Purchases Shares of 1,762,206 Arrowhead Pharmaceuticals IncRead the original story w/Photo

    Sunday Jun 10 | Daily Political

    Acuta Capital Partners LLC purchased a new position in shares of Arrowhead Pharmaceuticals Inc in the 1st quarter, Holdings Channel reports. The firm purchased 1,762,206 shares of the biotechnology company's stock, valued at approximately $12,706,000.

    Comment?

  6. 1,762,206 Shares in Arrowhead Pharmaceuticals Inc (ARWR) Purchased by Acuta Capital Partners LLCRead the original story w/Photo

    Sunday Jun 10 | AmericanBankingNews.com

    Acuta Capital Partners LLC bought a new position in shares of Arrowhead Pharmaceuticals Inc during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission . The fund bought 1,762,206 shares of the biotechnology company's stock, valued at approximately $12,706,000.

    Comment?

  7. Arrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClubRead the original story w/Photo

    Saturday Jun 9 | Daily Political

    ARWR has been the subject of a number of other research reports. B. Riley increased their price objective on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the company a neutral rating in a research note on Monday, February 12th.

    Comment?

  8. Arrowhead Pharmaceuticals Inc (ARWR) Position Increased by Uniplan Investment Counsel Inc.Read the original story w/Photo

    Friday Jun 8 | AmericanBankingNews.com

    Uniplan Investment Counsel Inc. increased its holdings in shares of Arrowhead Pharmaceuticals Inc by 1.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 724,228 shares of the biotechnology company's stock after purchasing an additional 10,506 shares during the quarter.

    Comment?

  9. Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635Read the original story w/Photo

    Friday Jun 8 | Business Wire

    The option grants entitle the employees, in aggregate, to purchase up to 101,000 shares of common stock. The strike price of options is set at an exercise price per share of $10.91, the last reported closing price of the Company's common stock on June 1, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company's common stock on the date of hire of four new employees, anticipated to be early in July.

    Comment?

  10. Arrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Earnings of -$0.19 Per ShareRead the original story w/Photo

    Monday Jun 4 | AmericanBankingNews.com

    Analysts expect Arrowhead Pharmaceuticals Inc to post earnings per share for the current fiscal quarter, according to Zacks . Four analysts have issued estimates for Arrowhead Pharmaceuticals' earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  11. Kenneth Allen Myszkowski Sells 14,000 Shares of Arrowhead Pharmaceuticals Inc (ARWR) StockRead the original story w/Photo

    Sunday Jun 3 | Daily Political

    Arrowhead Pharmaceuticals Inc CFO Kenneth Allen Myszkowski sold 14,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, May 31st. The shares were sold at an average price of $11.00, for a total value of $154,000.00.

    Comment?

  12. Arrowhead Pharmaceuticals (ARWR) Upgraded to "Strong-Buy" by BidaskClubRead the original story w/Photo

    Sunday Jun 3 | Daily Political

    A number of other brokerages have also weighed in on ARWR. Cantor Fitzgerald restated a buy rating and set a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday.

    Comment?

  13. Arrowhead Pharmaceuticals Inc (ARWR) CFO Kenneth Allen Myszkowski Sells 14,000 SharesRead the original story w/Photo

    Friday Jun 1 | AmericanBankingNews.com

    Arrowhead Pharmaceuticals Inc CFO Kenneth Allen Myszkowski sold 14,000 shares of the company's stock in a transaction on Thursday, May 31st. The shares were sold at an average price of $11.00, for a total value of $154,000.00.

    Comment?

  14. Arrowhead Pharmaceuticals (ARWR) Stock Price Up -4.2%Read the original story w/Photo

    Thursday May 31 | The Breeze

    Arrowhead Pharmaceuticals Inc shares rose 4.2% during mid-day trading on Thursday . The company traded as high as $11.00 and last traded at $10.65.

    Comment?

  15. Arrowhead Pharmaceuticals (ARWR) Sets New 52-Week High and Low at $11.00Read the original story w/Photo

    Wednesday May 30 | Daily Political

    Shares of Arrowhead Pharmaceuticals Inc reached a new 52-week high and low on Wednesday . The company traded as low as $11.00 and last traded at $10.74, with a volume of 159400 shares changing hands.

    Comment?

  16. Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBVRead the original story w/Photo

    Wednesday May 30 | Business Wire

    The company intends to submit a late-breaking abstract with initial clinical data on ARO-HBV to the Liver MeetingA 2018, the Annual Meeting of the American Association for the Study of Liver Disease , being held in November. AROHBV1001 is a Phase 1/2 study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses of ARO-HBV in healthy adult volunteers, and evaluating the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses of ARO-HBV in patients with chronic HBV.

    Comment?

  17. Trexquant Investment LP Invests $139,000 in Arrowhead Pharmaceuticals IncRead the original story w/Photo

    Tuesday May 29 | IntersportsWire

    Trexquant Investment LP acquired a new stake in Arrowhead Pharmaceuticals Inc in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 19,260 shares of the biotechnology company's stock, valued at approximately $139,000.

    Comment?

  18. Arrowhead Pharmaceuticals (ARWR) Receives Daily Coverage Optimism Rating of 0.19Read the original story w/Photo

    Monday May 28 | Daily Political

    News articles about Arrowhead Pharmaceuticals have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources.

    Comment?

  19. Brokerages Set Arrowhead Pharmaceuticals Inc (ARWR) PT at $9.00Read the original story w/Photo

    Saturday May 26 | The Breeze

    Arrowhead Pharmaceuticals Inc has earned a consensus recommendation of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

    Comment?

  20. Arrowhead Pharmaceuticals to Post FY2018 Earnings of ($0.76) Per...Read the original story w/Photo

    Thursday May 24 | AmericanBankingNews.com

    Arrowhead Pharmaceuticals - Equities research analysts at Cantor Fitzgerald lowered their FY2018 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 22nd. Cantor Fitzgerald analyst E. Piros now forecasts that the biotechnology company will earn per share for the year, down from their previous forecast of .

    Comment?